Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1

Interventions

pembrolizumab 3venetoclax 2selpercatinib 2obinutuzumab 2ibrutinib 2decitabine and cedazuridine drug combination 2cedazuridine 2Rituximab 2Nivolumab 2Midazolam 2Ipilimumab 2Decitabine 2Crizotinib 2zanubrutinib 1trametinib 1toripalimab 1tocilizumab 1tazemetostat 1tagraxofusp 1sotorasib 1sacituzumab govitecan 1romiplostim 1revumenib 1repotrectinib 1prednisolone phosphate 1prednisolone acetate 1pralsetinib 1polatuzumab vedotin 1pirtobrutinib 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Midazolam × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡